Lee David R, Chenoweth Matthew, Chuong Linh H, Villaflores Chad W, Cuevas Miguel, Vangala Sitaram, Borenstein Jeff, Kwak Hannah, Chima-Melton Chidinma, Han Maria, Skootsky Samuel A, Chan Tack Therese, Branagan Linda, Martin Heather, Gupta Reshma, Phan Linda, Sanchez Michael A, Malaak Mina M, Dermenchyan Anna, Pearson Kandyce N, Altunyan Marine, Barakat Peter F, Pablo Ray, Sarkisian Catherine
Division of Geriatrics, University of California, Los Angeles, Los Angeles, CA, United States.
Fielding School of Public Health, University of California, Los Angeles, Los Angeles, CA, United States.
JMIR Res Protoc. 2023 Oct 30;12:e45915. doi: 10.2196/45915.
Hypertension is a major contributor to various adverse health outcomes. Although previous studies have shown the benefits of home blood pressure (BP) monitoring over office-based measurements, there is limited evidence comparing the effectiveness of whether a BP monitor integrated into the electronic health record is superior to a nonintegrated BP monitor.
In this paper, we describe the protocol for a pragmatic multisite implementation of a quality improvement initiative directly comparing integrated to nonintegrated BP monitors for hypertension improvement.
We will conduct a randomized, comparative effectiveness trial at 3 large academic health centers across California. The 3 sites will enroll a total of 660 participants (approximately n=220 per site), with 330 in the integrated BP monitor arm and 330 in the nonintegrated BP control arm. The primary outcome of this study will be the absolute difference in systolic BP in mm Hg from enrollment to 6 months. Secondary outcome measures include binary measures of hypertension (controlled vs uncontrolled), hypertension-related health complications, hospitalizations, and death. The list of possible participants will be generated from a central data warehouse. Randomization will occur after enrollment in the study. Participants will use their assigned BP monitor and join site-specific hypertension interventions. Cross-site learning will occur at regular all-site meetings facilitated by the University of California, Los Angeles Value-Based Care Research Consortium. A pre- and poststudy questionnaire will be conducted to further evaluate participants' perspectives regarding their BP monitor. Linear mixed effects models will be used to compare the primary outcome measure between study arms. Mixed effects logistic regression models will be used to compare secondary outcome measures between study arms.
The study will start enrolling participants in the second quarter of 2023 and will be completed by the first half of 2024. Results will be published by the end of 2024.
This pragmatic trial will contribute to the growing field of chronic care management using remote monitoring by answering whether a hypertension intervention coupled with an electronic health record integrated home BP monitor improves patients' hypertension better than a hypertension intervention with a nonintegrated BP monitor. The outcomes of this study may help health system decision makers determine whether to invest in integrated BP monitors for vulnerable patient populations.
ClinicalTrials.gov NCT05390502; clinicaltrials.gov/study/NCT05390502.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): PRR1-10.2196/45915.
高血压是导致各种不良健康后果的主要因素。尽管先前的研究表明家庭血压监测比诊室测量更有益处,但比较集成到电子健康记录中的血压监测仪与非集成血压监测仪有效性的证据有限。
在本文中,我们描述了一项务实的多中心质量改进计划的方案,该计划直接比较集成式与非集成式血压监测仪对改善高血压的效果。
我们将在加利福尼亚州的3家大型学术医疗中心进行一项随机、比较有效性试验。这3个地点将总共招募660名参与者(每个地点约n = 220名),其中330名在集成血压监测仪组,330名在非集成血压对照组。本研究的主要结局将是从入组到6个月时收缩压(以毫米汞柱为单位)的绝对差值。次要结局指标包括高血压的二元指标(控制与未控制)、高血压相关的健康并发症、住院和死亡。可能的参与者名单将从中央数据仓库生成。随机分组将在研究入组后进行。参与者将使用他们分配的血压监测仪并参加特定地点的高血压干预措施。跨地点学习将在由加利福尼亚大学洛杉矶分校基于价值的医疗研究联盟主持的定期全地点会议上进行。将进行一项研究前和研究后的问卷调查,以进一步评估参与者对其血压监测仪的看法。线性混合效应模型将用于比较研究组之间的主要结局指标。混合效应逻辑回归模型将用于比较研究组之间的次要结局指标。
该研究将于2023年第二季度开始招募参与者,并将于2024年上半年完成。结果将于2024年底公布。
这项务实的试验将通过回答与电子健康记录集成的家庭血压监测仪相结合的高血压干预措施是否比使用非集成血压监测仪的高血压干预措施能更好地改善患者高血压,为使用远程监测的慢性护理管理这一不断发展的领域做出贡献。本研究的结果可能有助于卫生系统决策者确定是否应为弱势患者群体投资集成血压监测仪。
ClinicalTrials.gov NCT05390502;clinicaltrials.gov/study/NCT05390502。
国际注册报告识别码(IRRID):PRR1-10.2196/45915。